

## The epidemiological impact of digital and manual contact tracing on the SARS-CoV-2 epidemic in the Netherlands: empirical evidence.

**Authors:** Wianne Ter Haar<sup>1,2</sup>, Jizzo Bodriesz<sup>2,3</sup>, Roderick P. Venekamp<sup>1</sup>, Ewout Schuit<sup>1</sup>, Susan van den Hof<sup>4</sup>, Wolfgang Ebberts<sup>5</sup>, Mirjam Kretzschmar<sup>1,4</sup>, Jan Kluytmans<sup>1,6</sup>, Carl Moons<sup>1</sup>, Maarten Schim van der Loeff<sup>2,3</sup>, Amy Matser<sup>2,3</sup>, Janneke H. H. M. van de Wijgert<sup>1,4\*</sup>

\* Corresponding author

### Affiliations:

1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
2. Public Health Service (GGD) of Amsterdam, Amsterdam, Netherlands
3. Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
4. National Institute for Public Health and the Environment, Bilthoven, Netherlands
5. Department of Public Administration and Sociology, Erasmus University Rotterdam, Rotterdam, Netherlands
6. Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

### Correspondence:

Janneke van de Wijgert  
Julius Center for Health Sciences and Primary Care  
University Medical Center Utrecht  
Universiteitsweg 100, Stratenum room 7.127, 3584 CG Utrecht  
Phone: +31 88 75 68356  
Email: [j.h.h.vandewijgert@umcutrecht.nl](mailto:j.h.h.vandewijgert@umcutrecht.nl)

**Short title:** Impact of SARS-CoV-2 digital contact tracing.

**Keywords:** SARS-CoV-2, COVID-19, contact tracing, CoronaMelder application, Netherlands

### Word counts:

Abstract: 250  
Main text: 3,707  
References: 32  
Number of tables and figures: 4  
Supplements: 1

1 **Abstract**

2 **Background.** The Dutch government introduced the CoronaMelder smartphone application for digital  
3 contact tracing (DCT) to complement manual contact tracing (MCT) by Public Health Services (PHS)  
4 during the 2020-2022 SARS-CoV-2 epidemic. Modelling studies showed great potential but empirical  
5 evidence of DCT and MCT impact is scarce.

6 **Methods.** We determined reasons for testing, and mean exposure-testing intervals by reason for  
7 testing, using routine data from PHS Amsterdam (1 December 2020 to 31 May 2021) and data from  
8 two SARS-CoV-2 rapid diagnostic test accuracy studies at other PHS sites in the Netherlands (14  
9 December 2020 to 18 June 2021). Throughout the study periods, notification of DCT-identified  
10 contacts was via PHS contact-tracers, and self-testing was not yet widely available.

11 **Results.** The most commonly reported reason for testing was having symptoms. In asymptomatic  
12 individuals, it was having been warned by an index case. Only around 2% and 2-5% of all tests took  
13 place after DCT or MCT notification, respectively. About 20-36% of those who had received a DCT or  
14 MCT notification had symptoms at the time of test request. Test positivity after a DCT notification  
15 was significantly lower, and exposure-test intervals after a DCT or MCT notification were longer, than  
16 for the above-mentioned other reasons for testing.

17 **Conclusions.** Our data suggest that the impact of DCT and MCT on the SARS-CoV-2 epidemic in the  
18 Netherlands was limited. However, DCT impact might be enlarged if app use coverage is improved,  
19 contact-tracers are eliminated from the digital notification process to minimise delays, and DCT is  
20 combined with self-testing.

21 **Author summary**

22 During the 2020-2022 SARS-CoV-2 epidemic, the Dutch government introduced digital contact  
23 tracing (DCT) using a smartphone application to complement manual contact tracing (MCT) by  
24 professional contact-tracers. Mathematical models had suggested that DCT could slow down virus  
25 spread by identifying more individuals with whom the smartphone user had been in close contact  
26 and by reducing notification and testing delays after exposure. We used data collected during the  
27 Dutch epidemic to evaluate whether this was indeed the case and found that DCT and MCT had  
28 limited impact. Only around 2% of all tests took place after a DCT notification, and 2-5% after a MCT  
29 notification depending on MCT capacity at the time. Test positivity was lower after a DCT  
30 notification, and exposure-test intervals were longer after a DCT or MCT notification, than for other  
31 reasons for testing. About 20-36% of those who had received a DCT or MCT notification had  
32 symptoms at the time of test request and might have tested anyway even without having received  
33 the notification. However, DCT impact might be enlarged in future epidemics if app use coverage is  
34 improved and all exposure-notification-testing delays are minimised (e.g. no involvement of  
35 professional contact tracers and enabling self-testing after DCT notification).

## 36 Introduction

37 Source and contact tracing by public health professionals (manual contact tracing or MCT) is a well-  
38 known method to control the spread of communicable diseases, and was used during the 2020-2022  
39 SARS-CoV-2 pandemic. However, for the first time, digital contact tracing (DCT) using smartphone  
40 applications was also introduced in many countries worldwide (1–3). These apps differed in their  
41 levels of privacy-by-design, functionalities, and management of detected exposures. But they all had  
42 in common that a notification was triggered if the app user had been exposed to a person who had  
43 tested SARS-CoV-2-positive. In the Netherlands, the app was dubbed CoronaMelder. It was launched  
44 in the 8th month of the Dutch epidemic on 10 October 2020 (see *Supplementary introduction* for a  
45 detailed history of the Dutch epidemic) (4,5).

46  
47 DCT has several theoretical advantages over MCT and over testing because of having symptoms or  
48 having received a warning by an index case. These include identification and notification of more  
49 contacts (including contacts whom the app user does not know personally), reducing delays in  
50 becoming aware of an exposure or presymptomatic infection and getting tested, and increasing  
51 general awareness which might stimulate preventive behaviour (6). Modelling studies from various  
52 countries in the first year of the pandemic suggested that DCT might have a prominent  
53 epidemiological impact, but that the impact depends on user uptake, use coverage, percentage of  
54 exposures detected, testing capacity and policies, and the specifics and delays of the tracing process  
55 (7–10). More empirical evidence is needed to properly quantify these factors for use in future  
56 mathematical transmission models, which are needed to guide policy decisions regarding future  
57 investments in DCT and MCT (1,2). In this paper, we assessed whether DCT and MCT had added value  
58 in SARS-CoV-2 control during the 2020-2021 SARS-CoV-2 epidemic in the Netherlands. We focused  
59 on reasons for testing (including having received an exposure notification via DCT or MCT) and  
60 exposure-test intervals by reason for testing.

61

## 62 **Materials and Methods**

63 In the Netherlands, the general public could get tested at public health service (PHS) test sites (from  
64 1 June 2020 onwards), commercial test sites (between February 2021 and March 2022), and by self-  
65 testing (from 31 March 2021 onwards). Public testing was free-of-charge for specific indications, and  
66 initially included symptomatic individuals only. Free-of-charge testing of exposed but asymptomatic  
67 individuals with close contacts became possible from 1 December 2020 onwards: the initial  
68 recommendation was to test on the fifth day after exposure, but from 18 February 2021 onwards to  
69 also test as soon as possible after the exposure. Individuals who tested positive at public or  
70 commercial test sites were contacted by a PHS employee and asked about their recent contacts; until  
71 February 2022, individuals with a positive self-test were asked to do a repeat test at a PHS test site to  
72 confirm the result and to enter the PHS MCT programme. During times when the MCT programme  
73 was fully operational, PHS employees notified each reported close contact. However, MCT was  
74 regularly scaled down due to the programme being overwhelmed, and at those times, cases were  
75 asked to notify their close contacts themselves (*Supplementary methods*).


76

77 The CoronaMelder app was introduced on 10 October 2020 (technical explanations in the  
78 *Supplementary introduction* and Figure S1). By the end of May 2021, almost 30% of the Dutch  
79 population had downloaded the CoronaMelder app but only around 18% were still actively using it  
80 (5). For DCT to have epidemiological impact, all steps of the exposure-notification-action cascade  
81 should be optimised (Figure 1 and *Supplementary introduction*): app uptake and active use, detection  
82 of exposures, quarantine and testing once an exposure is detected, and isolation and notification of  
83 contacts after testing positive. App users who tested positive could voluntarily upload that  
84 information (via a so-called PHS-key) from the app to a backend server, which subsequently resulted  
85 in notifications being sent to all phones with CoronaMelder in active mode that had been within 1.5  
86 meters for at least 15 minutes within the last 14 days. PHS-keys could initially only be uploaded to  
87 the backend server after a PHS employee had entered the date of symptom onset or, if no symptoms

88 present, the date of the positive test into the PHS-key. From 11 November 2021 onwards (which is  
 89 after the three datasets used in this study had already been collected), app users could upload their  
 90 PHS-key themselves.

91

92 **Figure 1: The exposure-notification-action cascade during the SARS-CoV-2 epidemic in the**  
 93 **Netherlands, 2020-2021**



94

95 See *Supplementary introduction* for detailed explanations of each of these steps.

96

97 *Data sources*

98 We could not use data collected via CoronaMelder itself due to the privacy sensitive configuration of  
99 the app. Instead, we used routinely collected public health data at the PHS Amsterdam and data  
100 from two SARS-CoV-2 rapid diagnostic test (RDT) accuracy studies that were conducted at various  
101 other PHS test sites in the Netherlands.

102

103 PHS Amsterdam data were extracted from the national CoronIT, HPZone, and Osiris databases  
104 (described in the *Supplementary methods*). We plotted reasons for testing over time for the period 1  
105 June 2020 (start of public testing for symptomatic individuals) until 31 May 2021, but conducted all  
106 analyses on data collected between 1 December 2020 (DCT available, and DCT and MCT-notified  
107 asymptomatic close contacts could also access public testing) and 31 May 2021. The PHS Amsterdam  
108 dataset contained CoronIT data between 1 December 2020 and 31 May 2021 on age, gender, postal  
109 code, reason for testing, symptoms at the time of test request, date/time of test appointment,  
110 date/time of testing, and test result for 562,159 tests ( $n_t$ ) by 372,545 individuals ( $n_i$ ) (Figure S2).  
111 Exposure-testing intervals could only be determined for individuals who had been part of the PHS  
112 Amsterdam MCT programme as either a case or a contact (the PHS Amsterdam MCT subset). CoronIT  
113 data were merged with exposure date data from HPZone (available up to 31 March 2021) and  
114 exposure level data from Osiris. After merging, this PHS Amsterdam MCT subset included 20,647  
115 exposure-testing intervals ( $n_{e-t}$ ) by 20,355 individuals ( $n_i$ ) (Figure S2; merging process described in the  
116 *Supplementary methods*).

117

118 The first RDT study was conducted between 14 December 2020 and 6 February 2021 at PHS test sites  
119 in the West-Brabant (Raamsdonksveer and Roosendaal) and the Rotterdam-Rijnmond (Rotterdam  
120 The Hague Airport and Ahoy) regions. The second RDT study took place between 12 April and 18 June  
121 2021 at PHS test sites in the West-Brabant (Breda), Rotterdam-Rijnmond (Rotterdam The Hague  
122 Airport and Ahoy), and IJsselland (Zwolle) regions. The primary diagnostic accuracy results have been

123 published elsewhere (11,12). Participants provided written informed consent and had to be at least  
124 16 years. In the first RDT study, close contacts who were asymptomatic at the time of test request  
125 were eligible for participation, but about 9% of them had developed symptoms by the time of testing  
126 a few days later. The second RDT study included all individuals who scheduled a SARS-CoV-2 test at  
127 the participating PHS sites irrespective of reason for testing. In both studies, participants were asked  
128 to complete short questionnaires developed by the study teams – including questions about reasons  
129 for testing and CoronaMelder use – while waiting to be sampled at the test site (Figure S3). The  
130 questionnaire data were merged with the PHS test data including test results. The first RDT study  
131 dataset contained 4,126 individuals (Figure S4). The second RDT study dataset contained 7,925  
132 individuals but date of last exposure, and thereby an exposure-testing interval, was only available for  
133 3,172 individuals (Figure S4).

134

### 135 *Statistical analyses*

136 In all datasets, individuals could report multiple reasons for testing (Table 1 for an overview of these  
137 reasons). Symptoms could have been reported as a reason for testing, but anyone requesting a test  
138 or participating in one of the studies was also asked if they had any symptoms as a standalone  
139 question. These questions were asked at the time of test request in the PHS Amsterdam dataset and  
140 at the time of testing in the two RDT studies. In most analyses (unless noted otherwise below), we  
141 used a hierarchy to limit the number of reasons for testing categories. The hierarchy in the PHS  
142 Amsterdam dataset was DCT notification, MCT notification, having symptoms without notification,  
143 and unknown. The hierarchy in the first and second RDT studies, was DCT notification, MCT  
144 notification, followed by other types of notifications and other types of reasons for testing  
145 (*Supplementary methods*). We used the last date of exposure/contact, and the date a test sample  
146 was taken, to calculate the exposure-testing interval in all datasets.

147

148 Reasons for testing over time were displayed graphically. Population characteristics by reason for



149 testing were tabulated per data source and compared using Pearson's Chi-squared test for  
150 categorical variables and Kruskal-Wallis test for continuous variables. Adjusted standardized residuals  
151 of statistically significant categorical variables ( $p < 0.05$ ) were subsequently compared to the critical  
152 value, with p-values adjusted by the Bonferroni method. Continuous variables that differed  
153 statistically significantly between groups were subsequently analysed by Dunn Kruskal-Wallis  
154 multiple comparison test, with p-values adjusted by the Benjamini-Hochberg method. Mean  
155 exposure-testing intervals with standard deviations (SD) were calculated by reason for testing and by  
156 other population characteristics. Univariable and multivariable Weibull regression and tobit censored  
157 regression models were performed to estimate associations between characteristics and exposure-  
158 testing intervals. Reason for testing was included in these models as an indicator variable to allow for  
159 reporting of multiple reasons per person. Weibull models were a better fit than tobit models because  
160 testing peaked on day five after exposure, especially in the first RDT dataset. However, both types of  
161 models were fit, with tobit models considered a sensitivity analysis. In the PHS Amsterdam regression  
162 models, all individuals for whom an exposure-testing interval could be determined had been part of  
163 the MCT programme, and MCT was therefore not included as a variable. All statistical analyses were  
164 performed in R versions 3.6.3 or 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria).

165

## 166 **Results**

### 167 *Reasons for testing*

168 The main reason for testing over time was having symptoms, except in the first RDT study that only  
169 included asymptomatic close contacts (Table 1, Figure 2). In the PHS Amsterdam dataset, the overall  
170 percentage of test requests due to symptoms was 70.2% over the entire time period, but declined  
171 from a daily percentage between 73-97% in the period prior to 1 December 2020 to 60% on 31 May  
172 2021; the overall percentage in the second RDT study that took place in the second quarter of 2021  
173 was 45.2%. Having received a DCT notification, or having been contacted by the MCT programme,  
174 were minor reasons for testing in all three datasets over time. The percentages of test requests that


175 listed DCT as one of the reasons was 1.5% in the PHS Amsterdam dataset, 2.4% in the second RDT  
176 study, and 7.1% in the first RDT study in asymptomatic close contacts. These percentages were 4.9%,  
177 1.9%, and 12.3% for MCT, respectively. Direct notification by a housemate who tested positive or  
178 another index case (any other person who tested positive) was much more common than DCT and  
179 MCT notifications: 30% and 58.3% in the second and first RDT studies, respectively. In the first RDT  
180 study among asymptomatic close contacts, direct notification by index cases was consistently the  
181 main reason for testing over time.

182 **Table 1: Reasons for testing in the PHS Amsterdam, first RDT, and second RDT studies in the**  
 183 **Netherlands, 2020-2021**  
 184

Reasons for testing overall <sup>1</sup>	PHS Amsterdam n (% of total)	First RDT n (% of total)	Second RDT n (% of total)
Study period	01/12/20 – 31/05/21	14/12/20 – 06/02/21	12/04/21 – 14/06/21
Symptoms only	394,408 (70.2)	NA	3,586 (45.2)
Close contact <sup>2</sup>	35,744 (6.4)	3,688 (89.3)	3,682 (46.5)
Other reason <sup>3</sup>	NA	NA	259 (3.3)
Multiple reasons reported, including close contact <sup>4</sup>	NA	NA	48 (0.6)
Multiple reasons reported, not including close contact <sup>5</sup>	NA	NA	56 (0.7)
Unknown <sup>6</sup>	132,007 (23.5)	443 (10.7)	294 (3.7)
<b>Total</b>	<b>562,159</b>	<b>4,131</b>	<b>7,925</b>
<b>Reasons for testing by type of close contact</b>	<b>n (% of total, % of subtotal)</b>		
DCT notification	5,016 (0.9, 14.0)	228 (5.5, 6.2)	138 (1.7, 3.7)
MCT notification	18,894 (3.4, 52.9)	307 (7.4, 8.3)	40 (0.5, 1.1)
Index notification	NA	2,388 (57.8, 64.8)	1,495 (18.9, 40.1)
Housemate tested positive	NA	NA	414 (5.2, 11.1)
Self-referral (own initiative) <sup>2</sup>	NA	479 (11.6, 13.0)	240 (3.0, 6.4)
Combinations incl housemate <sup>7</sup>	NA	NA	466 (5.9, 12.5)
Combinations incl DCT, not housemate <sup>8</sup>	3,215 (0.6, 9.0)	65 (1.6, 1.8)	54 (0.7, 1.4)
Combinations incl MCT, not housemate or DCT <sup>9</sup>	8,619 (1.5, 24.1)	200 (4.8, 5.4)	112 (1.4, 3.0)
Other combinations <sup>10</sup>	NA	21 (0.5, 0.6)	0
Unknown type of notification <sup>11</sup>	NA	NA	771 (9.7, 20.7)
<b>Subtotal</b>	<b>35,744</b>	<b>3,688</b>	<b>3,730</b>
	<b>n (% of total, % of subtotal)</b>		
DCT alone or with other reasons	8,231 (1.5, 23.0)	293 (7.1, 7.9)	192 (2.4, 5.1)
MCT alone or with other reasons	27,932 (5.0, 78.1)	507 (12.3, 13.7)	152 (1.9, 4.1)

- 185 Abbreviations: DCT=digital contact tracing (CoronaMelder notification); GP=general practitioner; MCT=manual contact tracing (notification  
 186 by Public Health Service staff); NA=not applicable (symptoms as a reason for testing in the first RDT study) or not assessed (all other cases);  
 187 PHS=public health service; RDT=rapid diagnostic test.  
 188 1. Sample sizes are for number of tests and number of individuals in the first and second RDT study (one test per individual), and 562,159  
 189 tests by 372,545 individuals in the PHS Amsterdam dataset.  
 190 2. Close contact includes a DCT, MCT, index, housemate, or unknown notification, or testing at one's own initiative after someone tested  
 191 positive in the person's social circle (self-referral). Includes combinations of close contact notifications.  
 192 3. In the second RDT study, other reason included travel-related testing after having been in an orange- or red-coded country based on  
 193 SARS-CoV-2 risk (n=103), advised by the GP (n=75), or a different reason (n=81). The different reasons included having had a positive  
 194 self-test (n=10), work/school/event asked for a test (n=18), testing after 5-days of quarantine (n=4), precautionary testing (e.g. before  
 195 visiting an elderly relative) (n=43), and interested in finding out whether still positive (n=6).  
 196 4. In the second RDT study: close contact + GP (n= 37), close contact + travel (n=7), close contact + GP + travel (n=4).  
 197 5. In the second RDT study: symptoms + travel (n=6), symptoms + GP (n=50).  
 198 6. Data were not available: either the data were not recorded by contact tracing staff in the PHS Amsterdam dataset, or the question was  
 199 not answered by the RDT participants.  
 200 7. In second RDT study: housemate + DCT (n=18), housemate + MCT (n=53), housemate + index (n=288), housemate + DCT + MCT (n=8),  
 201 housemate + DCT + index (n=17), housemate + MCT+ index (n=69), housemate + DCT + MCT + index (n=13).  
 202 8. In the PHS Amsterdam dataset: DCT + symptoms (n=2,769), DCT + MCT (n=275), and DCT + MCT + symptoms (n=144). In the first RDT  
 203 study: DCT+MCT (n=4), DCT + index (n=38), DCT + self-referral (n=3; see 2 for definition), DCT + MCT + index (n=19), and DCT + MCT +  
 204 index + self-referral (n=1). In second RDT study: DCT + index (n=44), DCT + MCT + index (n=10).  
 205 9. In the PHS Amsterdam dataset: MCT + symptoms (n=8,619). In the first RDT study: MCT + index (n=189), MCT + self-referral (n=7; see 2  
 206 for definition), and MCT + index + self-referral (n=4). In the second RDT study, MCT + index (n=111), MCT + self-referral (n=1).  
 207 10. In the first RDT study: index + self-referral (n=21; see 2 for definition).  
 208 11. In the second RDT study this includes individuals who indicated that they had received an exposure notification but did not specify  
 209 which one.  
 210

211 **Figure 2: Reasons for testing over calendar time in the PHS Amsterdam, first RDT, and second RDT**  
 212 **datasets in the Netherlands, 2020-2021**  
 213



214 Abbreviations: DCT=digital contact tracing; Index=a person who tested SARS-CoV-2 positive; MCT>manual contact tracing; PHS=public  
 215 health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.  
 216 In Figure 1A, the first vertical dashed line represents the launch of the CoronaMelder app and the second one the change in testing policy,  
 217 allowing asymptomatic individuals to get tested after exposure to a close contact. Figure 1A is based on 908,060 tests by 560,775  
 218 individuals; 1B on 4,126 tests by 4,126 individuals; and 1C on 7,925 tests by 7,925 individuals.

219 Most test requests in the PHS Amsterdam dataset (72.2%) and the second RDT study (62.3%)  
220 included symptoms as one of the reasons for testing (Tables S1A and S1C). In the first RDT study,  
221 9.2% of asymptomatic close contacts developed symptoms by the time of testing (Table S1B).  
222 Furthermore, a substantial proportion of test requesters who reported a DCT or MCT notification  
223 also indicated the presence of symptoms (36% or 31% in the PHS Amsterdam dataset and 20% or  
224 28% in the second RDT study, respectively). Test population characteristics (such as age and gender)  
225 by reasons for testing are shown in Tables S1A-C and described in the Supplementary results.

226

#### 227 *Test positivity percentages*

228 The overall SARS-CoV-2 test positivity was roughly 9% in all datasets (Tables S1A-C). Test positivity in  
229 the DCT notification groups was lower than the overall test positivity in the PHS Amsterdam dataset  
230 (6.1%), first RDT study (3.4%), and second RDT study (3.7%), but this only reached statistical  
231 significance in the former two studies. Test positivity was statistically significantly higher than the  
232 overall test positivity in the MCT notification group of the PHS Amsterdam dataset (17.6%), and in  
233 the household (22.8%) and unknown notification (13.6%) groups in the second RDT study.

234

#### 235 *Mean exposure-testing intervals*

236 In the PHS Amsterdam MCT subset, first RDT study, and second RDT study, the mean exposure-  
237 testing intervals were 3.9 (SD 2.6), 4.9 (SD 1.5), and 4.3 (SD 2.0) days, respectively (Tables S2A-C). The  
238 DCT notification groups had similar or slightly shorter mean exposure-testing intervals (ranging from  
239 4.2 to 5.2 days) than the MCT notification groups (ranging from 4.5-5.1 days) in all three datasets, but  
240 longer intervals than the symptoms group (data available for the PHS Amsterdam MCT subset only;  
241 mean 3.1 days) and the household notification group (data available for the second RDT study only;  
242 mean 3.1 days). Mean exposure-testing intervals for having been notified by an index case or testing  
243 at one's own initiative were in between those for symptoms or household notification on the one  
244 hand and DCT or MCT notification on the other hand (Tables S2A-C). Mean exposure-testing intervals

245 by other test population characteristics are shown in Tables S2A-C and described in the  
246 Supplementary results.

247

#### 248 *Weibull regression models with exposure-testing interval as outcome*

249 The univariable Weibull models showed that testing after having received a DCT notification was  
250 associated with a statistically significantly 4-7% longer exposure-testing interval compared to all  
251 other reason for testing groups in all three datasets, but this only remained significant in the  
252 multivariable models of the PHS Amsterdam MCT subset and second RDT study (8% and 10%,  
253 respectively; Tables 2A-C). In uni- and multivariable Weibull models, testing after MCT notification  
254 was associated with a statistically significantly longer interval in the second RDT study (6% and 11%,  
255 respectively), testing after index case notification with a shorter interval in the first RDT study (5%  
256 and 5%, respectively), testing after a household notification with a shorter interval in the second RDT  
257 study (14% and 14%, respectively), and testing at one's own initiative with a longer interval in the  
258 second RDT study (9% and 11%, respectively). In the PHS Amsterdam MCT subset, individuals who  
259 were registered as cases or as household contacts had shorter exposure-testing intervals than non-  
260 household close contacts with long or short duration of contact (Table 2A). In the multivariable  
261 Weibull model excluding cases, testing after a household contact was associated with a significantly  
262 shorter interval than testing after a non-household close contacts with long or short duration of  
263 contact (Table 2A).

264

265 In the PHS Amsterdam MCT subset, testing because of symptoms was associated with statistically  
266 significantly shorter exposure-testing intervals (13-16%) in all regression models (Table 2A). In the  
267 second RDT study, intervals were not available for individuals who tested because of having  
268 symptoms. In the group who tested because of having been exposed to a positive individual,  
269 reporting symptoms was not significantly associated with a shorter interval in the univariable and/or  
270 multivariable models but trends in that direction were apparent (Table 2C).

271  
272

**Table 2A: Results of Weibull regression models for the interval between last exposure and testing in days – PHS Amsterdam MCT subset**

Coefficients	Univariable analysis <sup>1</sup> (n <sub>e,t</sub> = 20,647)			Multivariable analysis <sup>1</sup> (n <sub>e,t</sub> = 20,647)			Multivariable analysis contacts <sup>2</sup> (n <sub>e,t</sub> = 15,051)			Multivariable analysis asymptomatics <sup>3</sup> (n <sub>e,t</sub> = 11,992)		
	ETR <sup>4</sup>	95% CI	p-value	ETR <sup>4</sup>	95% CI	p-value	ETR <sup>4</sup>	95% CI	p-value	ETR <sup>4</sup>	95% CI	p-value
<b>Age:</b>												
0-14	1.10	1.08-1.12	<0.01	1.07	1.04-1.09	<0.01	1.08	1.06-1.10	<0.01	1.06	1.04-1.08	<0.01
15-29	reference	---	---	reference	---	---	reference	---	---	reference	---	---
30-44	1.02	1.00-1.04	0.04	1.01	0.99-1.03	0.24	1.05	1.03-1.07	<0.01	1.03	1.01-1.05	0.01
45-59	1.03	1.00-1.05	0.01	1.03	1.01-1.05	<0.01	1.04	1.02-1.06	<0.01	1.01	0.99-1.04	0.24
60+	1.08	1.05-1.11	<0.01	1.07	1.04-1.09	<0.01	1.07	1.04-1.10	<0.01	1.07	1.04-1.10	<0.01
<b>Gender:</b>												
Female	reference	---	---	reference	---	---	reference	---	---	reference	---	---
Male	1.02	1.01-1.04	<0.01	1.02	1.00-1.03	<0.01	1.02	1.01-1.04	<0.01	1.01	1.00-1.03	0.07
<b>Municipality:</b>												
Amsterdam	reference	---	---	reference	---	---	reference	---	---	reference	---	---
Surrounding	0.99	0.97-1.00	0.12	0.98	0.96-0.99	<0.01	0.97	0.96-0.99	<0.01	0.99	0.97-1.00	0.21
<b>Type of contact:<sup>5</sup></b>												
Household	reference	---	---	reference	---	---	reference	---	---	reference	---	---
Close, long	1.07	1.05-1.09	<0.01	1.07	1.06-1.09	<0.01	1.06	1.04-1.08	<0.01	1.01	1.00-1.03	0.10
Close, short	1.09	1.02-1.17	<0.01	1.10	1.03-1.17	<0.01	1.08	1.02-1.14	0.01	1.06	0.99-1.13	0.09
Other contact	1.00	0.86-1.17	0.99	1.00	0.85-1.16	0.98	0.98	0.85-1.13	0.77	1.01	0.86-1.20	0.88
Case	0.87	0.86-0.89	<0.01	0.91	0.89-0.92	<0.01	Not incl	---	---	0.88	0.87-0.90	<0.01
<b>DCT:</b>												
No	reference	---	---	reference	---	---	reference	---	---	reference	---	---
Yes	1.06	1.00-1.12	0.05	1.08	1.01-1.14	0.02	1.09	1.02-1.16	<0.01	1.10	1.03-1.18	<0.01
<b>Symptoms:</b>												
No	reference	---	---	reference	---	---	reference	---	---	Not included	---	---
Yes	0.84	0.83-0.85	<0.01	0.86	0.85-0.88	<0.01	0.87	0.85-0.88	<0.01	included	---	---
<b>Test result:</b>												
Negative	reference	---	---	Not included <sup>6</sup>	---	---	Not included <sup>6</sup>	---	---	Not included <sup>6</sup>	---	---
Positive	0.89	0.88-0.91	<0.01	---	---	---	---	---	---	---	---	---

Abbreviations: CI=confidence interval; DCT=digital contact tracing; ETR=event-time ratio; Index=a person who tested SARS-CoV-2 positive; MCT>manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.

1. Based on 20,647 exposure- testing intervals (n<sub>e,t</sub>) by 20,355 individuals (n) between 1 December 2020- 31 March 2021. Missing values for type of contact (n<sub>e,t</sub>= 69), test result (n<sub>e,t</sub>= 78), and gender (n<sub>e,t</sub>= 47).
2. Based on 15,051 exposure-test intervals (n<sub>e,t</sub>) in 14,827 individuals (n). Missing values for type of contact (n<sub>e,t</sub>= 69), test result (n<sub>e,t</sub>= 60) and gender (n<sub>e,t</sub>= 27).
3. Based on 11,992 exposure-test intervals (n<sub>e,t</sub>) in 11,855 asymptomatic individuals (n). Missing values for type of contact (n<sub>e,t</sub>= 40), test result (n<sub>e,t</sub>= 47) and gender (n<sub>e,t</sub>= 28).
4. The outcome measure is event time ratio (ETR). An ETR of 1.08 for having received a DCT notification can be interpreted as the relative increase in the time interval between exposure and testing by approximately 8 percent as compared to not having received a DCT notification.
5. "Close" is defined as within 1.5 meters of an infectious person; "long" as more than 15 minutes; "short" as 15 minutes or less but with high intensity (e.g. coughing in someone's face, kissing); "household" as a close contact within the same residence; and "other" as any other contact with an infectious person.
6. Test result was highly correlated with contact type and was therefore not included in the multivariable models.

273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284

285  
286

**Table 2B: Results of Weibull regression models for the interval between last exposure and testing in days – first RDT study**

Coefficients	Univariable analysis <sup>1</sup> (n= 3,646)			Multivariable analysis <sup>1</sup> (n= 3,646)		
	ETR <sup>2</sup>	95% CI	p-value	ETR <sup>2</sup>	95% CI	p-value
<b>Age:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	16-29	1.02	1.00-1.04	0.13	1.00-1.04	0.11
	30-44	1.00	0.98-1.02	0.95	0.97-1.01	0.58
	45-59	1.03	1.01-1.06	<0.01	1.02	1.00-1.05
<b>Gender:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	Female	1.00	0.98-1.02	0.97	1.00	0.98-1.01
<b>Testing region:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	Brabant	0.96	0.94-0.97	<0.01	0.97	0.95-0.98
<b>DCT:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	No	1.04	1.01-1.07	<0.01	1.00	0.96-1.04
<b>MCT:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	No	1.02	1.00-1.05	0.05	1.00	0.97-1.02
<b>Index:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	No	0.95	0.94-0.97	<0.01	0.95	0.92-0.98
<b>Self:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	No	1.02	1.00-1.04	0.12	0.97	0.94-1.01
<b>Unknown Contact:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	No	1.00	0.92-1.11	0.86	0.97	0.87-1.07
<b>Symptoms:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	No	1.02	0.99-1.05	0.14	1.03	1.00-1.06
<b>Test result:</b>	<i>reference</i>	---	---	<i>reference</i>	---	---
	Negative	0.98	0.96-1.01	0.25	0.98	0.96-1.01
	Positive					

287  
288  
289  
290  
291  
292  
293  
294

Abbreviations: CI=confidence interval; DCT=digital contact tracing; ETR=event-time ratio; Index=a person who tested SARS-CoV-2 positive; MCT>manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.

1. Includes 3,646 exposure-test intervals in 3,646 participants between 14 December 2020 - 6 February 2021. Only participants who reported a close contact were asked the date of last exposure and dates are missing (n=480) or not logical (before testing date or more than 14 days after testing, n=5). Additional missing values for symptoms (n=21), age (n=9), gender (n=14), and test location (n=9).
2. The outcome measure is event time ratio (ETR). An ETR of 1.04 for having received a DCT notification can be interpreted as the relative increase in the time interval between exposure and testing by approximately 4 percent as compared to not having received a DCT notification.



**Table 2C: Results of Weibull regression models for the interval between last exposure and testing in days – second RDT study**

		Univariable analysis <sup>1</sup> (n=3,172)			Multivariable analysis <sup>1</sup> (n=3,172)			Multivariable among asymptomatic <sup>2</sup> (n=2,179)		
Coefficients		ETR <sup>3</sup>	95% CI	p-value	ETR <sup>3</sup>	95% CI	p-value	ETR <sup>3</sup>	95% CI	p-value
<b>Age:</b>	16-29	reference	---	---	reference	---	---	reference	---	---
	30-44	1.03	1.00-1.06	0.08	1.01	0.98- 1.04	0.69	1.00	0.96- 1.03	0.92
	45-59	1.01	0.97- 1.04	0.73	1.01	0.97- 1.04	0.70	0.99	0.96- 1.03	0.76
	60+	1.03	0.98-1.08	0.20	0.98	0.93- 1.02	0.32	0.95	0.90- 1.00	0.07
<b>Gender:</b>	Female	reference	---	---	reference	---	---	reference	---	---
	Male	0.99	0.96- 1.01	0.35	0.99	0.97-1.02	0.49	0.99	0.96- 1.02	0.38
<b>Testing region:</b>	Brabant	reference	---	---	reference	---	---	reference	---	---
	Rotterdam	0.99	0.96-1.02	0.62	0.99	0.96- 1.02	0.68	0.98	0.95- 1.01	0.23
	Zwolle	0.96	0.93- 1.00	0.03	0.95	0.91-0.98	<0.01	0.97	0.93- 1.00	0.07
<b>DCT:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.07	1.02-1.13	<0.01	1.10	1.04 - 1.16	<0.01	1.05	0.99- 1.11	0.08
<b>MCT:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.06	1.01- 1.10	0.02	1.11	1.06 -1.16	<0.01	1.08	1.03- 1.13	<0.01
<b>Index:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.03	1.00- 1.05	0.04	1.04	0.99- 1.08	0.10	1.02	0.98- 1.07	0.30
<b>Housemate:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	0.86	0.84- 0.89	<0.01	0.86	0.83- 0.90	<0.01	0.92	0.88- 0.95	<0.01
<b>Self:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.09	1.03-1.16	<0.01	1.11	1.03 -1.19	<0.01	1.12	1.03- 1.21	<0.01
<b>Unknown Contact:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.02	0.98- 1.05	0.29	1.03	0.97- 1.08	0.34	1.05	0.99- 1.11	0.08
<b>Symptoms:</b>	No	reference	---	---	reference	---	---	Not included	---	---
	Yes	0.98	0.95- 1.00	0.08	0.98	0.95- 1.01	0.22	---	---	---
<b>Test result:</b>	Negative	reference	---	---	reference	---	---	reference	---	---
	Positive	0.93	0.89- 0.96	<0.01	0.95	0.92- 0.99	0.02	0.92	0.87- 0.97	<0.01
<b>Vaccinated:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.04	1.00- 1.08	0.07	1.03	0.99- 1.08	0.16	1.04	0.99- 1.09	0.09
<b>Previous infection:</b>	No	reference	---	---	reference	---	---	reference	---	---
	Yes	1.00	0.96- 1.04	0.95	1.00	0.95- 1.04	0.84	0.98	0.94- 1.03	0.37

Abbreviations: CI=confidence interval; DCT=digital contact tracing; ETR=event-time ratio; Index=a person who tested SARS-CoV-2 positive; MCT>manual contact tracing; PHS=public health service; RDT=rapid diagnostic test; Self=testing at one's own initiative.

1. Includes 3,172 exposure-test intervals in 3,172 participants between 12 April- 14 June 2021. Only participants who reported a close contact were asked the date of last exposure and dates are missing (n=519) or not logical (before testing date or more than 14 days after testing, n=39). Additional missing values for symptoms (n=13), age (n= 6), gender (n=9), vaccination status (n=1), and prior SARS-CoV-2 infection (n= 9).
2. 2,179 exposure-test intervals in 2,179 participants. Missing values for age (n= 4), gender (n=7), and prior SARS-CoV-2 infection (n= 3).
3. The outcome measure is event time ratio (ETR). An ETR of 1.04 for having received a DCT notification can be interpreted as the relative increase in the time interval between exposure and testing by approximately 4 percent as compared to not having received a DCT notification.

304 In the PHS Amsterdam MCT subset, individuals who ended up testing positive had a 11% shorter  
305 exposure-test interval than those who ended up testing negative (Table 2A). Similar trends were seen  
306 in the first and second RDT study (Tables 2B-C), but only reaching significance in the second RDT  
307 study (7% shorter in univariable and 5% shorter in the multivariable models). In the second RDT  
308 study, COVID-19 vaccination status and previous SARS-CoV-2 infection were not significantly  
309 associated with exposure-testing intervals (Table 2C). The tobit censored regression model results  
310 are shown in Tables S3A-C and described in the Supplementary results.

311

## 312 **Discussion**

313 We found that the epidemiological impact of both DCT and MCT were limited during the Dutch 2020-  
314 2022 SARS-CoV-2 epidemic. Only around 2% of all tests took place after a DCT notification, and 2-5%  
315 after a MCT notification depending on MCT capacity at the time. Additionally, test positivity among  
316 those testing after a DCT notification was significantly lower than among individuals testing for other  
317 reasons, the exposure-test intervals were longer after a DCT or MCT notification than for other  
318 reasons for testing, and about 20-36% of those who had received a DCT or MCT notification had  
319 symptoms at the time of test request and might have tested anyway even without having received  
320 the notification. These findings are in line with a self-evaluation performed by the Dutch PHS (GGD-  
321 GHOR) that found that the majority of tests at PHS test sites were not triggered by MCT or DCT  
322 notification, and test positivity was lower than average after DCT notification (13).

323

324 By the end of May 2021, almost 30% of the Dutch population had downloaded the CoronaMelder  
325 app but only around 18% were still actively using it (5). These percentages were similar to those in  
326 other countries that rolled out voluntary DCT: DCT apps were downloaded by 28% of the Norwegian  
327 population (14), 28% of the UK population (15), 26% of the Swiss population (declining to 22% active  
328 users over time) (16), 17% of the Canadian population (17), and use was reported by 21% of cases in  
329 Finland and 22% of cases in New South Wales, Australia (18). Direct comparisons between

330 epidemiological impact study results in these countries are not possible because of differences in  
331 how the contact-tracing apps were embedded within existing public health infrastructures,  
332 availability of data, and the degree of empirical evidence versus mathematical modelling used to  
333 estimate impact. However, overall, they showed only modest (14,15,19) to limited impact (5,18,20–  
334 22), with results being least pronounced when conclusions were predominantly based on empirical  
335 evidence.

336

337 Most impact studies cited low uptake as the main reason for the limited DCT impact, and several  
338 barriers to adoption have been identified: concerns about cybersecurity and privacy; lower levels of  
339 education, income, expectation about efficacy/perceived benefits, self-efficacy, and trust in  
340 government; higher age; and living in a community with lower levels of use (5,23–28). Several of these  
341 barriers are amenable to intervention, such as education and promotion campaigns. These campaigns  
342 were suboptimal in the Netherlands (5). In addition, combining DCT apps with other practical  
343 functionalities might have improved uptake. For example, the UK National Health Service (NHS)  
344 COVID-19 app included multiple functionalities and fared better than CoronaMelder: it was still  
345 regularly being used by around 28% of the British population by the end of December 2021 (15). These  
346 functionalities included a symptom checker connected to test requesting, a QR-scanner for checking  
347 into certain venues, and current government SARS-CoV-2 prevention guidelines in the local area. The  
348 Dutch government considered combining the functionalities of the CoronaMelder and CoronaCheck  
349 apps (to generate vaccination, test, and/or cure certificates) into one app, as has been done by other  
350 European governments such as Germany (Corona-Warn-App), Austria (The Stopp Corona App), and  
351 France (TousAntiCovid) (20,29), but eventually decided against this. This may have been a missed  
352 opportunity. The CoronaCheck app had been downloaded by 90% of the Dutch population by 1 March  
353 2022 (30).

354

355 Our analyses suggest that the PHS MCT programme did not contribute much to epidemic control

356 either. Unfortunately, we could not compare these findings to the above-mentioned impact studies  
357 because those studies did not place DCT in the wider context of other reasons for testing. In our  
358 study, most people in all three datasets tested because of having symptoms or because they  
359 themselves found out that someone in their social circle had tested positive. While MCT will likely  
360 continue to play an important role in the control of infectious diseases, its utility in the context of  
361 respiratory viruses that rapidly transmit within general populations should be re-evaluated. For  
362 example, instead of trying to maintain MCT at population level after containment has failed (which  
363 was regularly the case in the 2020-2022 Dutch SARS-CoV-2 epidemic), more focussed uses might be  
364 more appropriate and cheaper.

365

366 Unexpectedly, we found that DCT and MCT did not shorten delays between last exposure and testing  
367 compared to symptom-based testing. We hypothesise that suboptimal testing policies and  
368 CoronaMelder procedures are partly to blame for this. Between 1 December 2020 and 18 February  
369 2022, exposed but asymptomatic individuals were advised to test five days after exposure, hence the  
370 fairly uniform distribution of 5-day intervals in the first RDT study. Furthermore, when a  
371 CoronaMelder user tested positive, they had to wait for a PHS employee to contact them to be able  
372 to notify their contacts. A Swiss study reported that non-household MCT contacts who had also  
373 received a SwissCovid app notification generally went into quarantine a day earlier than non-  
374 household MCT contacts who had not received one (31). Nevertheless, the Swiss team also identified  
375 unnecessary delays due to several bottlenecks in the exposure-notification-action cascade, such as  
376 delayed delivery of codes for test result sharing, complex user interfaces, and misaligned incentives  
377 for subsequent mitigation behaviours (16).

378

379 The main limitations of our study relate to data availability and quality. To safeguard privacy, the only  
380 publicly accessible CoronaMelder-generated data are anonymous data on app downloads and active  
381 use (the number of smartphones connecting with the backend server) (5). We therefore had to use

382 proxy data sources. First, all three datasets that we used consisted mostly of self-reported data,  
383 which can suffer from misreporting and/or recall bias. For example, the last exposure date was not  
384 always available. Individuals who booked a test online had to consistently answer questions about  
385 CoronaMelder use to be able to make a booking, but these questions were less consistently asked  
386 and recorded when individuals booked a test by phone or within the MCT process (32). Second, test  
387 policies evolved over time. We already mentioned the day-5 test policy for individuals without  
388 symptoms. In addition, from 31 March 2021 onwards, self-testing became increasingly available and  
389 popular. The effects of this on our analyses are, however, limited because the three studies included  
390 in this report ran until mid-June 2021, before self-testing really took off. Third, we relied heavily on  
391 HPZone data for some of the PHS Amsterdam analyses, which limited the study population to  
392 individuals who had participated in the MCT programme. Furthermore, MCT capacity and guidelines  
393 fluctuated over time. Finally, we attempted to control for confounding in the multivariable models,  
394 but residual confounding cannot be excluded.

395

396 We conclude that both DCT and MCT had limited impacts on the Dutch 2020-2022 SARS-CoV-2  
397 epidemic. However, in future epidemics, the impact of DCT might be improved by concerted efforts  
398 to increase app use coverage, elimination of contact-tracers from the digital notification process to  
399 minimise delays, and ensuring that everyone who is notified can get tested right away, including by  
400 self-testing.

### **Acknowledgments**

We thank our colleagues at the various Public Health Services and associated laboratories, the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht, the National Institute for Public Health and the Environment (RIVM), and the Erasmus University Medical Center who contributed to the studies described in this paper.

### **Author contributions**

JHHMvdW, AM, and JB initiated and designed the study. WTH assembled and analysed the data with input from JB, AM, and JHHMvdW. ES, RV, SvdH, JK, CM, and JHHMvdW designed the questionnaires of the first and second RDT studies and implemented those studies. WTH and JHHMvdW wrote the first draft of this manuscript and all other authors critically read the manuscript and provided feedback.

### **Funding**

The first and second RDT studies were funded by the Dutch Ministry of Health, Welfare, and Sport. The funder had no role in study design; data collection and analysis, decision to publish, or preparation of the manuscript.

### **Competing interests**

JHHMvdW, JK, and CM were members of the Dutch Ministry of Health, Welfare, and Sport advisory committee on digital support of SARS-CoV-2 control. WE was a member of the Dutch Ministry of Health, Welfare, and Sport task force on digital support of SARS-CoV-2 control, and was commissioned by the Dutch Ministry of Health, Welfare and Sport to evaluate CoronaMelder.

### **Data availability**

PHS Amsterdam data are not publicly available for privacy reasons. Individual participant data of the two RDT studies will be made available, after deidentification, to researchers who provide a methodologically sound proposal. Proposals should be directed to Professor Carl Moons ([k.g.m.moons@umcutrecht.nl](mailto:k.g.m.moons@umcutrecht.nl)). Data requestors will need to sign a data access agreement.

## References

1. Braithwaite I, Callender T, Bullock M, Aldridge RW. Automated and partly automated contact tracing: a systematic review to inform the control of COVID-19. *Lancet Digit Health*. 2020 Nov 1;2(11):e607–21.
2. Jenniskens K, Bootsma MCJ, Damen JAAG, Oerbekke MS, Vernooij RWM, Spijker R, et al. Effectiveness of contact tracing apps for SARS-CoV-2: A rapid systematic review. *BMJ Open*. 2021 Jul 12;11(7):e050519.
3. Nebeker C, Kareem D, Yong A, Kunowski R, Malekinejad M, Aronoff-Spencer E. Digital exposure notification tools: A global landscape analysis. *medRxiv*. 2022 Jan 1;2022.06.02.22275925.
4. Kretzschmar MEE, Bruijning-Verhagen P, Bootsma MCJ, Bonten MJM, van de Wiggert JHHM. Digitale middelen in de strijd tegen COVID-19. *Ned Tijdschr Geneeskd*. 2020 Aug 14;164:D5280.
5. Ebbers W, Hooft L, van der Laan LN, Metting E. Evaluatie CoronaMelder: een overzicht na 9 maanden [Internet]. Ministerie van Volksgezondheid, Welzijn en Sport; 2021 [cited 2023 Feb 5]. Available from: <https://www.rijksoverheid.nl/documenten/publicaties/2021/05/28/rapporten-evaluatie-coronamelder-9-maanden>
6. Oliver N, Lepri B, Sterly H, Lambiotte R, Deletaille S, De Nadai M, et al. Mobile phone data for informing public health actions across the COVID-19 pandemic life cycle. *Sci Adv*. 2020 Jun;6(23):eabc0764.
7. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* [Internet]. 2020 May 8 [cited 2021 Jun 14];368(6491). Available from: <https://science.sciencemag.org/content/368/6491/eabb6936>
8. Kretzschmar ME, Rozhnova G, Bootsma MCJ, Boven M van, van de Wiggert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *Lancet Public Health*. 2020 Aug 1;5(8):e452–9.
9. Bradshaw WJ, Alley EC, Huggins JH, Lloyd AL, Esvelt KM. Bidirectional contact tracing could dramatically improve COVID-19 control. *Nat Commun*. 2021 Jan 11;12(1):232.
10. Kojaku S, Hébert-Dufresne L, Mones E, Lehmann S, Ahn YY. The effectiveness of backward contact tracing in networks. *Nat Phys*. 2021 May;17(5):652–8.
11. Schuit E, Veldhuijzen IK, Venekamp RP, Bijllaardt W van den, Pas SD, Lodder EB, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. *BMJ*. 2021 Jul 27;374:n1676.
12. Venekamp RP, Veldhuijzen IK, Moons KGM, van den Bijllaardt W, Pas SD, Lodder EB, et al. Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study. *BMC Med*. 2022 Feb 24;20(1):97.
13. Dolman TL. Tabellenrapport CoronaMelder GGD GHOR Nederland [Internet]. GGD GHOR Nederland; 2021 [cited 2023 Mar 9]. Available from: <https://www.rijksoverheid.nl/documenten/publicaties/2021/05/28/rapporten-evaluatie-coronamelder-9-maanden>

14. Elmokashfi A, Sundnes J, Kvalbein A, Naumova V, Reinemo SA, Florvaag PM, et al. Nationwide rollout reveals efficacy of epidemic control through digital contact tracing. *Nat Commun.* 2021 Oct 11;12(1):5918.
15. Wymant C, Ferretti L, Tsallis D, Charalambides M, Abeler-Dörner L, Bonsall D, et al. The epidemiological impact of the NHS COVID-19 app. *Nature.* 2021 May 12;1–5.
16. Daniore P, Nittas V, Ballouz T, Menges D, Moser A, Höglinger M, et al. Performance of the Swiss digital contact-tracing app over various SARS-CoV-2 pandemic waves: Repeated cross-sectional analyses. *JMIR Public Health Surveill.* 2022 Nov 11;8(11):e41004.
17. Sun S, Shaw M, Moodie EEM, Ruths D. The epidemiological impact of the Canadian COVID Alert app. *Can J Public Health Rev Can Sante Publique.* 2022 Aug;113(4):519–27.
18. Vogt F, Haire B, Selvey L, Katelaris AL, Kaldor J. Effectiveness evaluation of digital contact tracing for COVID-19 in New South Wales, Australia. *Lancet Public Health.* 2022 Mar 1;7(3):e250–8.
19. Menges D, Aschmann HE, Moser A, Althaus CL, von Wyl V. A data-driven simulation of the exposure notification cascade for digital contact tracing of SARS-CoV-2 in Zurich, Switzerland. *JAMA Netw Open.* 2021 Apr 1;4(4):e218184.
20. Ussai S, Pistis M, Missoni E, Formenti B, Armocida B, Pedrazzi T, et al. ‘Immuni’ and the national health system: Lessons learnt from the COVID-19 digital contact tracing in Italy. *Int J Environ Res Public Health.* 2022 Jun 20;19(12).
21. Rannikko J, Tamminen P, Hellsten R, Nuorti JP, Syrjänen J. Effectiveness of COVID-19 digital proximity tracing app in Finland. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2022 Jun;28(6):903–4.
22. Klinkenberg D, Leung KY, Wallinga J. CoronaMelder: modelstudie naar effectiviteit Digitaal contactonderzoek in de bestrijding van COVID-19 [Internet]. RIVM-briefrapport 2021-0092: Ministerie van Volksgezondheid, Welzijn en Sport; 2021 [cited 2023 Mar 9]. Available from: <https://www.rijksoverheid.nl/documenten/publicaties/2021/05/28/rapporten-evaluatie-coronamelder-9-maanden>
23. Ritsema F, Bosdriesz JR, Leenstra T, Petrignani MWF, Coyer L, Schreijer AJM, et al. Factors associated with using the COVID-19 mobile contact-tracing app among individuals diagnosed with SARS-CoV-2 in Amsterdam, the Netherlands: Observational study. *JMIR MHealth UHealth.* 2022 Aug 24;10(8):e31099.
24. Altmann S, Milsom L, Zillessen H, Blasone R, Gerdon F, Bach R, et al. Acceptability of app-based contact tracing for COVID-19: Cross-country survey study. *JMIR MHealth UHealth.* 2020 Aug 28;8(8):e19857.
25. Blom AG, Wenz A, Cornesse C, Rettig T, Fikel M, Friedel S, et al. Barriers to the large-scale adoption of a COVID-19 contact tracing app in Germany: Survey study. *J Med Internet Res.* 2021 Mar 2;23(3):e23362.
26. Walrave M, Waeterloos C, Ponnet K. Adoption of a contact tracing app for containing COVID-19: A Health Belief Model approach. *JMIR Public Health Surveill.* 2020 Sep 1;6(3):e20572.



27. Jansen-Kosterink S, Hurmuz M, den Ouden M, van Velsen L. Predictors to use mobile apps for monitoring COVID-19 symptoms and contact tracing: Survey among Dutch citizens. *JMIR Form Res.* 2021 Dec 20;5(12):e28416.
28. Waal NE van der, Wit J de, Bol N, Ebbers W, Hooft L, Metting E, et al. Predictors of contact tracing app adoption: Integrating the UTAUT, HBM and contextual factors. *Technol Soc.* 2022;71:102101.
29. Prodan A, Birov S, von Wyl V, Ebbers W. Covid-19 digital contact tracing study | Shaping Europe's digital future. Brussels. [Internet]. European Commission; 2022 [cited 2023 Mar 9]. Available from: [https://digital-strategy.ec.europa.eu/en/library/covid-19-digital-contact-tracing-study?pk\\_source=ec\\_newsroom&pk\\_medium=email&pk\\_campaign=dae%20Newsroom](https://digital-strategy.ec.europa.eu/en/library/covid-19-digital-contact-tracing-study?pk_source=ec_newsroom&pk_medium=email&pk_campaign=dae%20Newsroom)
30. Ministry of Health, Welfare, and Sports. Aantal downloads CoronaCheck-app en -Scanner [Internet]. CoronaCheck. [cited 2023 Feb 5]. Available from: <https://coronacheck.nl/nl/faq/7-13-actuele-downloadcijfers/#7>
31. Ballouz T, Menges D, Aschmann HE, Domenghino A, Fehr JS, Puhan MA, et al. Adherence and association of digital proximity tracing app notifications with earlier time to quarantine: Results from the Zurich SARS-CoV-2 Cohort Study. *Int J Public Health.* 2021;66:1603992.
32. Bente BE, van 't Klooster JWJR, Schreijer MA, Berkemeier L, van Gend JE, Slijkhuis PJH, et al. The Dutch COVID-19 contact tracing app (the CoronaMelder): Usability study. *JMIR Form Res.* 2021 Mar 26;5(3):e27882.

## Supporting information captions

Supplementary introduction

Supplementary methods

Supplementary results

Figure S1: CoronaMelder smartphone application

Figure S2: Participant flow diagram PHS Amsterdam datasets

Figure S3: Questionnaires used in the first RDT and second RDT studies (in Dutch language)

Figure S4: Participant flow diagrams first and second RDT studies

Table S1A: Test population characteristics by reason for testing – PHS Amsterdam

Table S1B: Test population characteristics by reason for testing – first RDT study (asymptomatic close contacts)

Table S1C: Test population characteristics by reason for testing – second RDT study

Table S2A: Mean (SD) interval in days between first exposure and testing – PHS Amsterdam MCT subset

Table S2B: Mean (SD) interval in days between last exposure and testing – first RDT study (asymptomatic close contacts)

Table S2C: Mean (SD) interval in days between last exposure and testing – second RDT study

Table S3A: Tobit regression model for exposure-test intervals – PHS Amsterdam MCT subset

Table S3B: Tobit regression model for the exposure-test intervals – first RDT study

Table S3C: Tobit regression model for the exposure-test intervals – second RDT study